Healios K.K (TSE:4593) - Stock Price, News & Analysis

4593 Stock Overview

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.

About the company

4593 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 39.36% per year

Revenue grew by 34.4% over the past year

Risk Analysis

Makes less than USD$1m in revenue (¥121M)

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

Does not have a meaningful market cap (¥13B)

+ 1 more risk

Healios K.K. Competitors

3-D Matrix

TSE:7777

JP¥9.4b

AnGes

TSE:4563

JP¥9.9b

Cuorips

TSE:4894

JP¥26.2b

ReproCELL

TSE:4978

JP¥12.0b

Price History & Performance

Summary of all time highs, changes and price drops for Healios K.K
Historical stock prices
Current Share Price	JP¥147.00
52 Week High	JP¥332.00
52 Week Low	JP¥114.00
Beta	0.93
1 Month Change	5.00%
3 Month Change	1.38%
1 Year Change	-48.42%
3 Year Change	-91.10%
5 Year Change	-92.11%
Change since IPO	-91.29%

Recent updates

Shareholder Returns

	4593	JP Biotechs	JP Market
7D	1.4%	0.2%	-0.5%
1Y	-48.4%	-25.1%	28.3%

Return vs Industry: 4593 underperformed the JP Biotechs industry which returned -25.1% over the past year.

Return vs Market: 4593 underperformed the JP Market which returned 28.3% over the past year.

Price Volatility

Is 4593's price volatile compared to industry and market?
4593 volatility
4593 Average Weekly Movement	8.4%
Biotechs Industry Average Movement	8.1%
Market Average Movement	4.1%
10% most volatile stocks in JP Market	8.1%
10% least volatile stocks in JP Market	2.3%

Stable Share Price: 4593 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4593's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.

About the Company

Founded	Employees	CEO	Website
2011	64	Hardy Kagimoto	www.healios.co.jp

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013.

Healios K.K. Fundamentals Summary

How do Healios K.K's earnings and revenue compare to its market cap?
4593 fundamental statistics
Market cap	JP¥13.25b
Earnings (TTM)	-JP¥3.82b
Revenue (TTM)	JP¥121.00m

109.5x

P/S Ratio

-3.5x

P/E Ratio

Is 4593 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4593 income statement (TTM)
Revenue	JP¥121.00m
Cost of Revenue	JP¥13.00m
Gross Profit	JP¥108.00m
Other Expenses	JP¥3.93b
Earnings	-JP¥3.82b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 13, 2024

Earnings per share (EPS)	-42.42
Gross Margin	89.26%
Net Profit Margin	-3,159.50%
Debt/Equity Ratio	114.0%

How did 4593 perform over the long term?

See historical performance and comparison

4593 Stock Overview

Rewards

Risk Analysis

Healios K.K. Competitors

TSE:7777

JP¥9.4b

TSE:4563

JP¥9.9b

TSE:4894

JP¥26.2b

TSE:4978

JP¥12.0b

Price History & Performance

Recent News & Updates

New major risk - Share price stability

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Healios K.K. to Report Q1, 2024 Results on May 13, 2024

Consensus revenue estimates increase by 64%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Recent updates

New major risk - Share price stability

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Healios K.K. to Report Q1, 2024 Results on May 13, 2024

Consensus revenue estimates increase by 64%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Healios K.K., Annual General Meeting, Mar 27, 2024

Healios K.K. and Procellcure Inc. Announce Start of Ards Clinical Trial in Japan

Healios K.K. announced that it expects to receive ¥2.2600715 billion in funding

Healios K.K. and Its Wholly Owned Subsidiary ProcellCure Inc. Announce Submission of ARDS Clinical Trial Notification in Japan

Consensus EPS estimates upgraded to JP¥56.76 loss

Healios K.K. to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings released: JP¥9.98 loss per share (vs JP¥12.31 loss in 3Q 2022)

Consensus revenue estimates increase by 130%

New minor risk - Market cap size

HEALIOS K.K. Conducts the Treasure Study to Investigate the Safety and Efficacy of HLCM051

Healios K.K. to Report Q3, 2023 Results on Nov 14, 2023

HEALIO K.K. Provides its Innovative eNK Platform for A Novel Research Study on Metastatic Uveal Melanoma At Thomas Jefferson University in Philadelphia

Price target increased by 11% to JP¥845

Second quarter 2023 earnings released: JP¥10.37 loss per share (vs JP¥32.62 loss in 2Q 2022)

Healios K.K. Announces Use of 3D Bioreactor-Based Manufacturing Method Produced Product for ARDS

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Healios K.K. to Report Q2, 2023 Results on Aug 14, 2023

Healios K.K. Announces Submission of Clinical Trial Notification for RPE Tail Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

First quarter 2023 earnings released: JP¥11.52 loss per share (vs JP¥26.47 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to JP¥60.13 loss

Price target decreased by 19% to JP¥762

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Healios K.K. Announces Management Changes

Forecast to breakeven in 2025

High number of new directors

Healios K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: JP¥12.31 loss per share (vs JP¥34.86 loss in 3Q 2021)

Healios K.K. announced that it has received ¥100.0316 million in funding from SATAKE Corporation

HEALIOS Announces Results from the TREASURE Study

Healios K.K. announced that it expects to receive ¥100.0316 million in funding from SATAKE Corporation

Healios K.K. NK Cells Demonstrate Anti-Tumor Effect in Lung Cancer Patient-Derived Cancer Organoids

Healios K.K. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

First half 2022 earnings released: JP¥59.11 loss per share (vs JP¥36.60 loss in 1H 2021)

Healios K.K. to Report Q2, 2022 Results on Aug 10, 2022

Healios K.K. Reports Top-Line Results from Treasure Study for Ischemic Stroke

First quarter 2022 earnings released: JP¥26.47 loss per share (vs JP¥19.92 loss in 1Q 2021)

Price target decreased to JP¥2,760

Less than half of directors are independent

Healios K.K. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to JP¥2,760

Healios K.K. Announces Completion of 365 Days Post-Administration Follow Up for TREASURE Study for Patients with Ischemic Stroke

Healios K.K. Provides Progress Update in Relation to Application for Approval for HLCM051 for ARDS

Full year 2021 earnings released: JP¥93.36 loss per share (vs JP¥107 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Healios K.K., Annual General Meeting, Mar 25, 2022

Healios K.K. Announces Announcement of Change in Management